Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Tvardi Therapeutics (TVRD)
at www.tipranks.com (Wed, 4-Nov 4:30 AM)
Roche’s Phase 3 sefaxersen readout highlights a 43.1% proteinuria reduction in IgA nephropathy for Ionis
Market Chameleon (Mon, 26-Oct 8:33 AM)
Ionis reports Phase 3 FUSION win for ulefnersen, with a primary endpoint that combines function and survival
Market Chameleon (Tue, 22-Sep 8:59 AM)
